文献速递胸部肿瘤

奈达铂联合多西他赛对比顺铂联合多西他赛一线治疗晚期肺鳞癌的III期随机试验

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial.
PubMed 文献 · J Thorac Oncol · 2018-07-11

这项在中国12家医院开展的多中心、开放标签、随机III期试验,比较奈达铂(80 mg/m2)联合多西他赛(75 mg/m2)(ND)与顺铂(75 mg/m2)联合多西他赛(75 mg/m2)(CD)一线治疗晚期肺鳞癌的疗效。意向治疗分析(ND组n=141,CD组n=139)显示,中位无进展生存期(PFS)在ND组为4.63个月、CD组为4.23个月(p=0.056),两组间无显著差异。结论认为ND方案未改善PFS,但ND组血液学毒性更多、CD组非血液学毒性更多,ND可作为晚期或复发肺鳞癌的新治疗选择。

要点

  • ND与CD方案在意向治疗人群中PFS无显著差异(p=0.056)。
  • ND组最佳总缓解率51.5%优于CD组38.1%(p=0.033)。
  • ND组血液学毒性更多,CD组非血液学毒性(如恶心、乏力)更多。

核心结论

  • 意向治疗分析中,奈达铂联合多西他赛(ND)相比顺铂联合多西他赛(CD)未改善无进展生存期。
  • ND组血液学毒性更多,CD组非血液学毒性更多,ND可作为晚期或复发肺鳞癌的新治疗选择。

研究设计与样本

  • 多中心、开放标签、随机对照III期试验,在中国12家医院开展。
  • 患者随机接受四个周期的ND(奈达铂80 mg/m2+多西他赛75 mg/m2)或CD(顺铂75 mg/m2+多西他赛75 mg/m2)。
  • 主要终点为无进展生存期(PFS),次要终点包括至进展时间、最佳总缓解和不良事件。
  • 意向治疗分析集:ND组n=141,CD组n=139。

主要发现

  • ND组中位PFS为4.63个月(95%CI:4.43-5.10),CD组为4.23个月(95%CI:3.37-4.53),p=0.056。
  • 两组至进展时间无显著差异。
  • ND组最佳总缓解率为51.5%,CD组为38.1%(p=0.033);疾病控制率组间比较p=0.0004。
  • CD组III或IV级不良事件及3-4级恶心、乏力较ND组更常见(均p<0.05)。

关键数值与推荐

  • ND方案:奈达铂80 mg/m2联合多西他赛75 mg/m2,共四周期。
  • CD方案:顺铂75 mg/m2联合多西他赛75 mg/m2,共四周期。
  • 主要终点PFS:ND组4.63个月(95%CI:4.43-5.10)对比CD组4.23个月(95%CI:3.37-4.53),p=0.056。
  • 最佳总缓解率:ND组51.5%对比CD组38.1%(p=0.033);疾病控制率比较p=0.0004。

临床怎么用

  • 对于晚期肺鳞癌一线治疗,ND方案PFS未优于CD方案,但缓解率更高且非血液学毒性较少。
  • ND方案血液学毒性更多,选择时需结合患者耐受性个体化评估。

局限性

  • 为开放标签设计,未设盲。
  • 原文未报告总生存期结果。
  • 研究仅在中国12家医院开展,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study aimed to compare the efficacy of first-line nedaplatin (80 mg/m2) plus docetaxel (75 mg/m2) (ND) versus cisplatin (75 mg/m2) plus docetaxel (75 mg/m2) (CD) in patients with advanced squamous cell lung carcinoma. METHODS: This open-label randomized controlled phase III trial was performed at 12 hospitals in China. Patients with squamous cell lung carcinoma were randomized to four cycles of ND or CD. The primary endpoint was progression-free survival (PFS). Secondary endpoints included time to progression, best overall response, and adverse events. RESULTS: In the intent-to-treat analysis set (ND: n = 141; CD: n = 139), median PFS was 4.63 months (95% confidence interval: 4.43-5.10) for the ND and 4.23 months (95% confidence interval: 3.37-4.53) for CD groups (p = 0.056). No significant difference in time to progression was observed between the two groups. Best overall responses and disease control rate were better with ND 51.5%, than with CD 38.1% (p = 0.033 and p = 0.0004, respectively). Grade III or IV adverse events and grade 3-4 nausea and fatigue were more frequent in the CD group compared with the ND group (all p < 0.05). CONCLUSIONS: There is no improvement in PFS with the nedaplatin and docetaxel combination in the intent-to-treat analysis. More hematologic toxicities were observed in the ND group (compared with CD), whereas more nonhematologic toxicities were observed in the CD group. ND could be a new treatment option for advanced or relapsed squamous cell lung cancer (NCT02088515 at ClinicalTrials.gov).

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Lu S, Chen Z, Hu C, et al. Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial. J Thorac Oncol. 2018. PMID: 30017831. doi:10.1016/j.jtho.2018.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。